AR081364A1 - Composiciones farmaceuticas de pazopanib y metodos para su elaboracion - Google Patents

Composiciones farmaceuticas de pazopanib y metodos para su elaboracion

Info

Publication number
AR081364A1
AR081364A1 ARP110101514A ARP110101514A AR081364A1 AR 081364 A1 AR081364 A1 AR 081364A1 AR P110101514 A ARP110101514 A AR P110101514A AR P110101514 A ARP110101514 A AR P110101514A AR 081364 A1 AR081364 A1 AR 081364A1
Authority
AR
Argentina
Prior art keywords
pazopanib
solution
modified cyclodextrin
milligrams
milliliter
Prior art date
Application number
ARP110101514A
Other languages
English (en)
Original Assignee
Glaxo Wellcome Mfg Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Wellcome Mfg Pte Ltd filed Critical Glaxo Wellcome Mfg Pte Ltd
Publication of AR081364A1 publication Critical patent/AR081364A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Abstract

Reivindicacion 1: Una composicion farmacéutica, la cual comprende: una cantidad de una sal de adicion de ácido de pazopanib equivalente a aproximadamente 10 miligramos de base libre de pazopanib/mililitro de la composicion; de aproximadamente el 2.0 a aproximadamente el 13.0 por ciento en peso/peso de una ciclodextrina modificada que es adecuada para utilizarse en una formulacion oftálmica, seleccionándose la ciclodextrina modificada de tal manera que la ciclodextrina modificada dé como resultado la pKa de pazopanib en una solucion de 10 miligramos de pazopanib/mililitro de agua con una cantidad dada de ciclodextrina modificada que sea más baja que la pKa de pazopanib en una solucion de 10 miligramos de pazopanib/mililitro de agua; si es necesario, un agente de ajuste del pH para proporcionar un pH de 3.5 a 5.7; si es necesario, un agente de ajuste de tonicidad para proporcionar una osmolaridad de 200 a 400 mOsm; y agua; en donde la composicion es estable durante cuando menos 2 meses. Reivindicacion 38: Un método para la preparacion de una solucion super- saturada de pazopanib, comprendiendo este método: 5 formar una solucion acuosa de una sal de adicion de ácido de pazopanib y una ciclodextrina modificada adecuada para utilizarse en una formulacion oftálmica; y ajustar el pH de la solucion entre 3.5 a 5.7, para obtener una solucion super-saturada de pazopanib, en donde la lo concentracion de la sal de adicion de ácido de pazopanib solubilizada en la solucion super-saturada es equivalente a aproximadamente 10 miligramos/mililitro de la base libre de pazopanib.
ARP110101514A 2010-05-05 2011-05-03 Composiciones farmaceuticas de pazopanib y metodos para su elaboracion AR081364A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33171510P 2010-05-05 2010-05-05

Publications (1)

Publication Number Publication Date
AR081364A1 true AR081364A1 (es) 2012-08-29

Family

ID=44851507

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110101514A AR081364A1 (es) 2010-05-05 2011-05-03 Composiciones farmaceuticas de pazopanib y metodos para su elaboracion

Country Status (26)

Country Link
US (3) US20120028918A1 (es)
EP (1) EP2566331B1 (es)
JP (1) JP5835717B2 (es)
KR (1) KR20130071434A (es)
CN (1) CN102970871A (es)
AR (1) AR081364A1 (es)
AU (1) AU2011247995B2 (es)
BR (1) BR112012028291A2 (es)
CA (1) CA2798386A1 (es)
CL (1) CL2012003075A1 (es)
CO (1) CO6640262A2 (es)
CR (1) CR20120556A (es)
DO (1) DOP2012000281A (es)
EA (1) EA201291168A1 (es)
ES (1) ES2519615T3 (es)
HK (1) HK1175947A1 (es)
IL (1) IL222751A0 (es)
MA (1) MA34286B1 (es)
MX (1) MX2012012837A (es)
NZ (1) NZ603411A (es)
PE (1) PE20130217A1 (es)
SG (1) SG185087A1 (es)
TW (1) TW201206908A (es)
UY (1) UY33367A (es)
WO (1) WO2011140343A1 (es)
ZA (1) ZA201208265B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
ES2493641T3 (es) * 2007-06-28 2014-09-12 Cydex Pharmaceuticals, Inc. Administración nasal de soluciones acuosas de corticosteroides
US8623395B2 (en) 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
WO2013022801A1 (en) 2011-08-05 2013-02-14 Forsight Vision4, Inc. Small molecule delivery with implantable therapeutic device
TW201206908A (en) * 2010-05-05 2012-02-16 Glaxo Wellcome Mfg Pte Ltd Pharmaceutical compositions and methods of making same
PT2600930T (pt) 2010-08-05 2021-03-22 Forsight Vision4 Inc Aparelho injetor e método para distribuição de fármacos
WO2012068549A2 (en) 2010-11-19 2012-05-24 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
EP3903733A1 (en) 2011-09-16 2021-11-03 ForSight Vision4, Inc. Fluid exchange apparatus
JP2015507020A (ja) * 2012-02-17 2015-03-05 ファーマサイクリックス，インク． ヒストンデアセチラーゼ阻害剤とパゾパニブの組み合わせおよびその使用
EP3509387B1 (en) * 2012-03-08 2021-07-28 Samsung Electronics Co., Ltd. Method for controlling services in wireless communication system
US9968603B2 (en) 2013-03-14 2018-05-15 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
US11136625B2 (en) 2013-08-28 2021-10-05 Crown Bioscience, Inc. (Taicang) Gene expression signatures predictive of subject response to a multi-kinase inhibitor and methods of using the same
AU2015301054B2 (en) 2014-08-08 2020-05-14 Forsight Vision4, Inc. Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
AU2015346450B2 (en) 2014-11-10 2020-01-30 Forsight Vision4, Inc. Expandable drug delivery devices and method of use
US11129900B2 (en) 2014-12-25 2021-09-28 Kyoto University Cytophilic peptide-fused high-density lipoprotein, and delivery of drug to posterior segment of eye by ocular installation of said fusion
ES2837524T3 (es) 2016-04-05 2021-06-30 Forsight Vision4 Inc Dispositivos de administración de fármacos oculares implantables
CN110769853B (zh) * 2017-04-17 2022-06-03 北京生命科学研究所 治疗雄性衰老
WO2019028104A1 (en) * 2017-08-02 2019-02-07 Alphala Co., Ltd. NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME
MX2020013238A (es) * 2018-06-07 2021-02-22 Pfizer Formulacion acuosa que comprende 1-(4-{[4-(dimetilamino)piperidin- 1-il]carbonil}fenil)-3-[4-(4,6-dimorfolin-4-il-1,3,5-triazin-2-il )fenil]urea.
CN113350351A (zh) * 2020-03-13 2021-09-07 青晓制药公司 帕唑帕尼的应用、药物组合物、注射液及制备方法和应用
US20240050429A1 (en) * 2022-08-10 2024-02-15 Qx Therapeutics, Inc. Pazopanib pharmaceutical composition, injection and preparation method and use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8904296D0 (sv) * 1989-12-21 1989-12-21 Pharmacia Ab Transdermal system
US7893040B2 (en) * 2005-07-22 2011-02-22 Oculis Ehf Cyclodextrin nanotechnology for ophthalmic drug delivery
BRPI0619057A2 (pt) * 2005-11-29 2011-09-20 Smithkline Beecham Corp formulação farmacêutica de uso tópico, uso de um ou mais compostos, e, compostos
AR059066A1 (es) * 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
CN101484136A (zh) * 2006-04-18 2009-07-15 Ekr治疗公司 预混合的、立即可用的药物组合物
CA3105972A1 (en) * 2007-10-19 2009-04-30 Novartis Ag Compositions and methods for treatment of diabetic retinopathy
WO2009097446A1 (en) * 2008-01-30 2009-08-06 Genentech, Inc. Pyrazolopyrimidine pi3k inhibitor compounds and methods of use
BR112012001030A2 (pt) * 2009-07-16 2019-09-24 Glaxo Wellcome Mfg Pte Ltd método para tratar a degeneração macular, e, uso de um composto.
WO2011039648A1 (en) * 2009-09-30 2011-04-07 Glaxo Wellcome Manufacturing Pte Ltd. Methods of administration and treatment
UY33164A (es) * 2010-01-06 2011-08-31 Glaxo Wellcome Mfg Pte Ltd Metodo de tratamiento
US20130023550A1 (en) * 2010-05-05 2013-01-24 Glaxo Wellcome Manufacturing Pte, Ltd Pharmaceutical compositions and methods of making same
TW201206908A (en) * 2010-05-05 2012-02-16 Glaxo Wellcome Mfg Pte Ltd Pharmaceutical compositions and methods of making same

Also Published As

Publication number Publication date
JP2013525501A (ja) 2013-06-20
JP5835717B2 (ja) 2015-12-24
AU2011247995A1 (en) 2012-12-13
TW201206908A (en) 2012-02-16
HK1175947A1 (en) 2013-07-19
CR20120556A (es) 2013-02-20
KR20130071434A (ko) 2013-06-28
EP2566331A1 (en) 2013-03-13
DOP2012000281A (es) 2013-05-31
US20110281901A1 (en) 2011-11-17
MA34286B1 (fr) 2013-06-01
US20120028918A1 (en) 2012-02-02
MX2012012837A (es) 2013-01-24
AU2011247995B2 (en) 2014-07-31
ES2519615T3 (es) 2014-11-07
EP2566331A4 (en) 2013-09-18
EA201291168A1 (ru) 2013-06-28
NZ603411A (en) 2014-10-31
UY33367A (es) 2011-10-31
ZA201208265B (en) 2013-07-31
EP2566331B1 (en) 2014-09-03
US20150231265A1 (en) 2015-08-20
PE20130217A1 (es) 2013-03-21
CL2012003075A1 (es) 2013-03-08
CO6640262A2 (es) 2013-03-22
IL222751A0 (en) 2012-12-31
BR112012028291A2 (pt) 2015-09-15
WO2011140343A1 (en) 2011-11-10
CN102970871A (zh) 2013-03-13
SG185087A1 (en) 2012-12-28
CA2798386A1 (en) 2011-11-10

Similar Documents

Publication Publication Date Title
AR081364A1 (es) Composiciones farmaceuticas de pazopanib y metodos para su elaboracion
CL2017002488A1 (es) Formulación farmacéutica estable para administración intratecal que comprende una proteína arilsulfatasa a (asa), sal y un tensoactivo de polisorbato y/o un agente amortiguador, y que además puede contener un agente estabilizante; contenedor que comprende dicha formulación; uso para tratar la enfermedad leucodistrofia metacrómatica (mld). (divisional solicitud 3654-2012)
AR113034A2 (es) Formulación líquida de un conjugado de la hormona del crecimiento humano de efecto prolongado
EA201291108A1 (ru) Фармацевтические композиции в виде эмульсии с низким содержанием масла, содержащие прогестоген
HRP20171256T1 (hr) Farmaceutski pripravci karbetocina
AR116874A2 (es) Composición de glifosato para mezclas de tanque con dicamba con volatilidad mejorada
CL2008003762A1 (es) Composicion concentrada en suspension acuosa para proteccion de cultivos, que comprende un compuesto activo y como agentes estabilizadores, un disperzante no ionico y un dsipersante anionico y agua; metodos para preparacion de dicha composicion y usos de la misma, para el cuidado de cultivos de interes.
BR112015008186A2 (pt) formulação de um anticorpo estável e de baixa viscosidade
BR112013003934A2 (pt) depot de fosfolipídeos
CO6270302A2 (es) Formulaciones solidas de liberacion rapida que incluyen florfenicol y sales farmaceuticamente aceptables del mismo.
CL2013003163A1 (es) Composición transdermica de ibuprofeno, util en el tratamiento del dolor o la inflamacion.
AR065963A1 (es) Solucion acuosa de peroxido de hidrogeno, proceso para su preparacion y su uso
AR094012A1 (es) Composiciones estables con peroxido para el cuidado oral
AR086651A1 (es) Dentifrico de ion metalico con bajo contenido de agua
ES2720954T3 (es) Formulaciones estabilizadas de estatina
AR091039A1 (es) Composiciones farmaceuticas topicas que comprenden terbinafina, uso y metodo de tratamiento
PH12015500864A1 (en) Liquid formulation comprising gm-csf neutralizing compound
MX2016014411A (es) Formulacion liquida que comprende un compuesto neutralizante de gm-csf.
BR112012026659A2 (pt) composto para desinfecção de superfícies.
CL2013002810A1 (es) Composicion farmaceutica solida oral que comprende a) un compuesto 2-amino-2-[2-(4-octil-fenil)-etil]-propano-1,3-diol (fingolimod) en una cantidad de 0,5 mg o menos, o una sal del mismo, b) un relleno y c) un estabilizante que comprende una ciclodextrina; y su uso para tratar una enfermedad autoinmune tal como esclerosis multiple.
AR088067A1 (es) Metodo para reducir la transpiracion y composiciones antitranspirantes
AR089269A1 (es) Composiciones para el cuidado oral
GT201400027A (es) Acuosa suspensión concentrada que comprende un ácido sal de dodecilguanidina
AR074709A1 (es) Sales, composiciones liquidas acuosas que contienen sales de acido s-(+)-abscisico y metodos de su preparacion
AR092691A1 (es) Composicion farmaceutica que comprende rebamipida

Legal Events

Date Code Title Description
FB Suspension of granting procedure